Definium Therapeutics, Inc.

NASDAQ:DFTX

Biotechnology

Healthcare
$29.12 -1.67%

-$0.41 today

Market cap
$3.99B
Beta
2.38
P/E (TTM)
-11.0
EPS (TTM)
-$2.18
52W Low $12.88High $26.15

Volume 1.91M

Average 2.67M

DFTX Net Income

Bottom-line profit, the starting point for calculating cash from operations.

Definium Therapeutics, Inc.NASDAQ: DFTX

Net Income · Q3 FY2026 · quarter ended Sep 2026

Net income dips below year-ago levels

Q3 FY2026 net income of $50.96M (cash outflow) fell 24.2% year over year, behind the +100.8% change in trailing-twelve-month net income. Sequentially, it fell 67.9% from the prior quarter. Over 3 fiscal years it compounded at +47.9% a year.

Context

  • Net income grew in size in 3 of the last 3 fiscal years.
  • FY2025 was the largest annual figure in the 4 fiscal years shown.

What to watch

Whether net income reaches the consensus estimate of -$199.16M (+8.4%) for the fiscal year ending Dec 2026, a slowdown from the +69.1% reported in FY2025.

Sources:Cash Flow Analyst consensus estimates Text generated from reported figures; not investment advice.

Latest quarterSep 2026
-$50.96M-67.9% QoQ
Last fiscal yearDec 2025
-$183.79M+69.1% YoY
LTMSep 2026
-$337.48M+100.8% YoY
Net Income past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-24.2%-3.5%+20.8 pp
1 year+69.1%+8.4%-60.8 pp
3-year CAGR+47.9%-32.4%-80.3 pp
5-year CAGR——
10-year CAGR——

Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.

Net Income history

USD · from the cash flow

Latest · FY2025
(183.79M) USD
Year-over-year change
-69.1%
Reported Analyst consensus estimate Further estimates hidden. Sign in to unlock

Net Income vs competitors

How DFTX compares with its peers on the latest reported figures

  • Peers report in different currencies, so net income is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of +100.8% is the 2nd highest of 9, against a peer median of +24.6%.
  • Over three fiscal years its annual growth of +47.9% compares with a peer median of +25.5%.
DFTX Competitors
Net Income for DFTX and competitors
Company Period LTM YoY 3-year CAGR% of revenue
NERVMinerva Neurosciences, Inc.LTM Jun 2026$108.22B USD—+109.1%—
PRAXPraxis Precision Medicines, Inc.LTM Sep 2026$359.43M USD+31.6%+12.3%—
DFTXDefinium Therapeutics, Inc.LTM Sep 2026$337.48M USD+100.8%+47.9%—
NMRANeumora Therapeutics, Inc. Common StockLTM Mar 2026$222.39M USD-13.8%+21.9%—
MPLTMapLight Therapeutics, Inc.LTM Mar 2026$199.48M USD+146.3%+75.1%—
AXSMAxsome Therapeutics, Inc.LTM Jun 2026$191.64M USD-22.4%-0.7%24.7%
RAPPRapport Therapeutics, Inc. Common StockLTM Mar 2026$107.28M USD+34.6%+118.7%536.4%
ANROAlto Neuroscience, Inc.LTM Mar 2026$74.31M USD+17.6%+31.7%—
GHRSGH Research PLCLTM Mar 2026$56.41M USD+34.0%+29.0%—
LBRXLB Pharmaceuticals Inc Common StockLTM Mar 2026$39.17M USD—+20.7%—
ATHEAlterity Therapeutics LimitedFY2025A$12.15M AUD-36.5%-1.8%223.4%
Peer median (excluding DFTX) —+24.6%+25.5%223.4%

Competitors are the stored peer set for DFTX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(93.04M)(56.8M)(95.73M)(108.68M)(183.79M)
Depreciation & Amortization2.62M3.18M3.16M527K0
Deferred Income Tax(1.16M)0(2.03M)00
Stock-Based Compensation42.72M13.71M15.49M16.91M20.1M
Change in Working Capital1.88M(3.78M)6.28M(3.34M)9.44M
Accounts Receivables00000
Inventory00000
Accounts Payables1.28M(2.06M)2.03M(2.13M)3.34M
Other Working Capital598K(1.73M)4.26M(1.22M)6.1M
Other Non-Cash Items1.16M(6.45M)8.46M15.45M22.7M
Operating Cash Flow(45.82M)(50.14M)(64.37M)(79.13M)(131.56M)
Capital Expenditures00000
Acquisitions (Net)(297K)0000
Purchases of Investments0000(268.36M)
Sales of Investments0000116.75M
Other Investing Activities00000
Investing Cash Flow(297K)000(151.61M)
Debt Repayment0014.16M10.86M20M
Common Stock Issued81.92M42.3M7.53M250M259.9M
Common Stock Repurchased00000
Dividends Paid00000
Other Financing Activities16.9M16.75M163K(7.66M)(12.63M)
Financing Cash Flow98.82M59.05M21.85M253.2M267.27M
Effect of Forex Changes742K(309K)79K(30K)(7K)
Net Change in Cash53.45M8.6M(42.44M)174.04M(15.9M)
Free Cash Flow(45.82M)(50.14M)(64.37M)(79.13M)(131.56M)

Definium Therapeutics, Inc.

NASDAQ:DFTX

Intrinsic Alpha fair value

Locked

Current Price

$29.12

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.